Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Nintedanib in lung cancer: added benefit depends on disease severity

2015-04-01 In non-small cell lung cancer the new angiokinase inhibitor has advantages in patients without brain metastases, but disadvantages in patients with brain metastases.  read more Link to "Nintedanib in lung cancer: added benefit depends on disease severity"

Open-angle glaucoma: poor data for the fixed combination tafluprost/timolol

2015-04-01 As the study results are uncertain and information on important outcomes is lacking, no added benefit can be determined for the fixed combination of tafluprost and timolol.  read more Link to "Open-angle glaucoma: poor data for the fixed combination tafluprost/timolol"

Enzalutamide: indication of major added benefit

2015-04-01 In comparison with watchful waiting, the new drug can prolong survival in certain patients with prostate cancer and delay the occurrence of disease complications.  read more Link to "Enzalutamide: indication of major added benefit"

Sipuleucel-T in prostate cancer: indication of added benefit

2015-03-19 Information subsequently submitted by the drug manufacturer provided better evidence on mortality. However, it is not possible to exactly estimate the extent of added benefit.  read more Link to "Sipuleucel-T in prostate cancer: indication of added benefit"

Early benefit assessment increases transparency for study data

2015-03-02 In the British Medical Journal, IQWiG researchers award good grades to the German Act on the Reform of the Market for Medicinal Products (AMNOG). The Act has revealed a large amount of information on… read more Link to "Early benefit assessment increases transparency for study data"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
N14-04 Procedure for lung volume reduction in severe lung emphysema on the report plan 2015-05-04

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Lurasidone (Latuda) for schizophrenia

Lurasidone (trade name: Latuda) has been approved since March 2014 for the treatment of schizophrenia in adults.  read more (Link to "Lurasidone (Latuda) for schizophrenia" – opens in a new window)

to top

Glossary entries